Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy.
EuroIntervention. 2011 Sep;7(5):573-9. doi: 10.4244/EIJV7I5A93.
Transcatheter aortic valve implantation (TAVI) is an emerging alternative to medical therapy reserved to a limited population with severe aortic stenosis. Quality-of-life (QoL) is a critical measure of effectiveness of TAVI in this patient population. In this prospective study, we sought to assess one year changes in QoL in patients who underwent TAVI.
From June 2007 to July 2010, 149 consecutive patients underwent TAVI using the 18 Fr CoreValve (Medtronic Inc, Minneapolis, MN, USA) or the Edwards SAPIEN XT heart valve (Edwards Lifescience, Irvine, CA, USA) at our institution. Of these, 143 patients with successful prosthesis implantation comprised the study population. The SF-12v2 Health-Survey questionnaire provides scales for physical (physical component summary [PCS]) and mental (mental component summary [MCS]) health. Among patients included in the present analysis, device success was obtained in 138 patients (96.5%). Mean preprocedural SF-12v2 scores showed an important upgrading after TAVI: PCS improved from 28.3 to 44.0 at five months and 42.4 at 12 months (p<0.001). MCS increased from 38.0 to 47.3 at five months and 48.2 at 12 months (p<0.001). Both the physical and mental score summaries at follow-up of these post-TAVI patients were not significantly different from the anticipated thresholds of the general Italian population over the age of 75 years. NYHA functional class improvement was reported in all patients.
Our results showed a marked mid-term improvement in functional status and physical and mental health in patients who underwent TAVI.
经导管主动脉瓣置换术(TAVI)是一种新兴的替代疗法,适用于严重主动脉瓣狭窄的有限人群。生活质量(QoL)是 TAVI 在这一患者群体中有效性的关键衡量标准。在这项前瞻性研究中,我们旨在评估接受 TAVI 的患者一年来 QoL 的变化。
2007 年 6 月至 2010 年 7 月,我们机构对 149 例连续患者进行了 TAVI 治疗,使用 18Fr CoreValve(美敦力公司,明尼苏达州明尼阿波利斯市)或 Edwards SAPIEN XT 心脏瓣膜(爱德华生命科学公司,加利福尼亚州欧文市)。其中,143 例成功植入假体的患者纳入研究人群。SF-12v2 健康调查问卷提供了身体(身体成分综合评分 [PCS])和心理(心理成分综合评分 [MCS])健康的评分。在本分析中包括的患者中,138 例患者(96.5%)获得了器械成功。SF-12v2 的平均术前评分显示 TAVI 后有显著改善:PCS 在 5 个月时从 28.3 提高到 44.0,12 个月时提高到 42.4(p<0.001)。MCS 在 5 个月时从 38.0 提高到 47.3,12 个月时提高到 48.2(p<0.001)。这些接受 TAVI 治疗的患者的随访时的身体和心理评分总和与 75 岁以上意大利普通人群的预期阈值没有显著差异。所有患者均报告 NYHA 功能分级改善。
我们的结果显示,接受 TAVI 的患者的功能状态以及身体和心理健康在中期有显著改善。